ArticleInternal medicine (Tokyo, Japan)2020
Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- [Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
- Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.Frontiers in oncology · 2026Review
- Microsatellite-high intrahepatic cholangiocarcinoma with favorable treatment outcome using pembrolizumab.Clinical journal of gastroenterology · 2025Article
- Review
- Effective control in MSI-high unresectable intrahepatic cholangiocarcinoma treated with gemcitabine/cisplatin/durvalumab and proton beam therapy: a case report.Frontiers in immunology · 2025Article
- Pathological Complete Response after Pembrolizumab Treatment for Unresectable Perihilar Cholangiocarcinoma with High Microsatellite Instability: A Case Report.Surgical case reports · 2025Article
- New perspectives in biliary tract cancers.ESMO gastrointestinal oncology · 2024Review
- Review
- Discrepancy among microsatellite instability detection methodologies in non-colorectal cancer: Report of 3 cases.World journal of clinical cases · 2023Article
- A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab.Cureus · 2023Article
- Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?Cancers · 2023Review
- Review
- Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors.Cancers · 2022Review
- Flower-like Composite Material Delivery of Co-Packaged Lenvatinib and Bufalin Prevents the Migration and Invasion of Cholangiocarcinoma.Nanomaterials (Basel, Switzerland) · 2022Article
- Targeted Therapies for Perihilar Cholangiocarcinoma.Cancers · 2022Review
- Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population.Oncology letters · 2022Article
- Article
- Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.Clinical journal of gastroenterology · 2021Article
- Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.Clinical journal of gastroenterology · 2021Article
- Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 60-year-old man presented with postoperative recurrence of intrahepatic cholangiocarcinoma with right portal vein tumor thrombosis (PVTT). After failure of standard chemotherapy, a liver biopsy showed that his microsatellite instability (MSI) status was high. Treatment with the immune checkpoint inhibitor (ICI) pembrolizumab was commenced, which resulted in a partial response and resolution of the PVTT. There were no significant immune-related adverse events. According to recently published reports, the frequency of MSI-high biliary tract cancer (BTC) is about 0-2.1%, which is extremely rare. However, ICIs may be effective in patients with MSI-high BTC, such as the present patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.